1. A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus 
Amit G. Singal, Michael L. Volk, Donald Jensen, Adrian M. Di Bisceglie, Philip S. Schoenfeld 
Clinical Gastroenterology and Hepatology 
Volume 8, Issue 3, Pages e1 (March 2010)
DOI: /j.cgh
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Liver-related mortality rates. (A) Annual liver-related mortality rate in treatment failures for HCV patients with all stages of fibrosis. (B) Annual liver-related mortality rate in treatment failures for HCV patients with advanced fibrosis or cirrhosis. (C) RR of liver-related mortality in patients achieving SVR versus treatment failures among HCV patients with all stages of fibrosis. (D) RR of liver-related mortality in patients achieving SVR versus treatment failures among HCV patients with advanced fibrosis or cirrhosis.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
HCC rates. (A) HCC rate in treatment failures for HCV patients with all stages of fibrosis. (B) HCC rate in treatment failures for HCV patients with advanced fibrosis or cirrhosis. (C) RR of HCC in patients achieving SVR versus treatment failures among HCV patients with all stages of fibrosis. (D) RR of HCC in patients achieving SVR versus treatment failures among HCV patients with advanced fibrosis or cirrhosis.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
Hepatic decompensation rates. (A) Hepatic decompensation rate in treatment failures for HCV patients with all stages of fibrosis. (B) Hepatic decompensation rate in treatment failures for HCV patients with advanced fibrosis or cirrhosis. (C) RR of hepatic decompensation in patients achieving SVR versus treatment failures among HCV patients with all stages of fibrosis. (D) RR of hepatic decompensation in patients achieving SVR versus treatment failures among HCV patients with advanced fibrosis or cirrhosis.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

5. Figure 4
RR of HCC between patients with primary nonresponse to antiviral therapy versus relapsers.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

6. Supplementary Figure 1 Map of literature search.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions